Citadel Advisors
ALLO icon

Citadel Advisors’s Allogene Therapeutics ALLO Stock Holding History

Citadel Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$149K Buy
71,800
+10,300
+17% +$22.6K ﹤0.01% 12354
2026
Q1 		$150K Sell
61,500
-17,100
-22% -$34.3K ﹤0.01% 11681
2025
Q4 		$108K Buy
78,600
+52,000
+195% +$68.6K ﹤0.01% 11574
2025
Q3 		$33K Sell
26,600
-45,400
-63% -$54.1K ﹤0.01% 12375
2025
Q2 		$81.4K Sell
72,000
-2,400
-3% -$3.19K ﹤0.01% 11487
2025
Q1 		$109K Buy
74,400
+17,700
+31% +$33.4K ﹤0.01% 11342
2024
Q4 		$121K Buy
56,700
+51,300
+950% +$127K ﹤0.01% 11171
2024
Q3 		$15.1K Sell
5,400
-8,300
-61% -$22.1K ﹤0.01% 12987
2024
Q2 		$31.9K Buy
13,700
+11,000
+407% +$32.5K ﹤0.01% 12197
2024
Q1 		$12.1K Sell
2,700
-6,400
-70% -$26.7K ﹤0.01% 13377
2023
Q4 		$29.2K Buy
9,100
+3,200
+54% +$9.08K ﹤0.01% 12288
2023
Q3 		$18.7K Sell
5,900
-8,800
-60% -$38.6K ﹤0.01% 12680
2023
Q2 		$73.1K Sell
14,700
-5,800
-28% -$31.4K ﹤0.01% 11344
2023
Q1 		$101K Buy
20,500
+6,000
+41% +$38.5K ﹤0.01% 11245
2022
Q4 		$91.2K Sell
14,500
-9,800
-40% -$90.7K ﹤0.01% 11346
2022
Q3 		$262K Buy
24,300
+1,100
+5% +$14.9K ﹤0.01% 9860
2022
Q2 		$264K Sell
23,200
-5,700
-20% -$50.6K ﹤0.01% 10102
2022
Q1 		$263K Sell
28,900
-13,500
-32% -$141K ﹤0.01% 10891
2021
Q4 		$633K Buy
42,400
+16,100
+61% +$284K ﹤0.01% 9086
2021
Q3 		$676K Buy
26,300
+11,700
+80% +$278K ﹤0.01% 9158
2021
Q2 		$381K Buy
14,600
+700
+5% +$20K ﹤0.01% 10684
2021
Q1 		$491K Sell
13,900
-2,600
-16% -$87.7K ﹤0.01% 9712
2020
Q4 		$416K Sell
16,500
-2,400
-13% -$78.2K ﹤0.01% 8478
2020
Q3 		$713K Sell
18,900
-9,100
-33% -$343K ﹤0.01% 6650
2020
Q2 		$1.2M Buy
28,000
+10,400
+59% +$376K ﹤0.01% 5492
2020
Q1 		$342K Buy
17,600
+5,100
+41% +$121K ﹤0.01% 7094
2019
Q4 		$325K Buy
12,500
+3,900
+45% +$107K ﹤0.01% 7467
2019
Q3 		$234K Sell
8,600
-5,100
-37% -$145K ﹤0.01% 7937
2019
Q2 		$368K Sell
13,700
-5,800
-30% -$162K ﹤0.01% 7274
2019
Q1 		$564K Buy
19,500
+1,600
+9% +$46.4K ﹤0.01% 6599
2018
Q4 		$482K Buy
+17,900
New +$476K ﹤0.01% 6445

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors's ALLO Position: Q2 2026 in Review

Citadel Advisors increased its Allogene Therapeutics (ALLO) stake by 48% in Q2 2026, buying an estimated $7.23M and bringing the position to 10,087,770 shares worth $21M. The position accounts for ﹤0.01% of the portfolio, ranked #2518.

Citadel Advisors first reported a position in ALLO in Q4 2018 and has held it in 31 quarters since. The position peaked at $35.4M in Q4 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Citadel Advisors held 10,087,770 shares of Allogene Therapeutics worth $21M as of Q2 2026.
  • Citadel Advisors bought 3,294,150 Allogene Therapeutics shares in Q2 2026, an estimated $7.23M.
  • Allogene Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2518 holding.
  • Citadel Advisors first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 31 quarters since.
  • Citadel Advisors's Allogene Therapeutics position peaked at $35.4M in Q4 2021.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.